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Objectives: We assessed differences in antiretroviral treatment (ART) coverage and virological suppression across three HIV key populations, as defined by self-reported HIV transmission category: sex between men, injection drug use (IDU) and heterosexual transmission.
Design: A multinational cohort study.
Methods: Within the EuroSIDA study, we assessed region-specific percentages of ARTcoverage among those in care and virological suppression (<500 copies/ml) among those on ART, and analysed differences between transmission categories using logistic regression.
Results: Among 12 872 participants followed from 1 July 2014 to 30 June 2016, the percentages of ART-coverage and virological suppression varied between transmission categories, depending on geographical region (global P for interaction: P ¼ 0.0148 for ART-coverage, P ¼ 0.0006 for virological suppression). In Western [adjusted odds ratio (aOR) 1.41 (95% confidence interval 1.14- However, a scarcity of data disaggregated by key population deprives programme implementers the possibility to target interventions that ensure the timely diagnosis, treatment and care needed to maximize individual health benefits and reduce the risk of onward transmission [7] [8] [9] [10] [11] . Previous EuroSIDA work showed country-level and regional variation in ART-coverage and virological suppression among people on ART [4] . We hypothesized that these estimates may mask differences between key populations, and aimed to assess regional variation in levels of ARTcoverage and virological suppression among three key populations, as categorized by HIV transmission category: people infected through sex between men, heterosexual contact or injecting drug use (IDU).
Materials and methods

Patients
People were included from the EuroSIDA cohort study, which holds data from more than 23 000 people living [4, 12] .
Statistics
In the period 1 July 2014-30 June 2016, EuroSIDA participants were considered 'in care' if their first EuroSIDA visit occurred before the end of the period and their latest recorded visit or CD4 þ cell count or HIV-RNA measurement occurred after the start of the period. Participants were assessed for being 'in care', 'on ART' or 'virologically suppressed' at the latest of a clinic visit, CD4 þ cell count or HIV-RNA measurement, or at the midpoint of the period if all these dates were unavailable.
In a cross-sectional analysis, we assessed the percentage receiving ART among those in care, and the percentage virologically suppressed among those on ART, stratified by HIV transmission category. ART was defined as receiving at least three antiretrovirals from any class, and virological suppression was defined as HIV-RNA below 500 copies/ml at the most recent measurement within 12 months prior to assessment [4] . If participants in care had no available HIV-RNA measurement in the period, they were considered unsuppressed (missing ¼ failure).
Logistic regression modelled the odds ratio (OR) of receiving ART among those in care, and of being virologically suppressed among those on ART. We adjusted for factors hypothesized to vary across regions and transmission categories: current age, sex, CD4 þ at entry into EuroSIDA and current hepatitis B virus (HBV) and hepatitis C virus (HCV) status. Formal tests for interaction were used to assess regional differences in the odds of receiving ART and being virologically suppressed by HIV transmission category.
Results
We included a total 12 872 EuroSIDA participants in care between 1 July 2014 and 30 June 2016 ( (Fig. 1) . However, these crude estimates varied by region (Fig. 2) . Figure 2 shows the percentage receiving ART among those in care and the percentage virologically suppressed among those on ART. This means that each step uses the previous step as denominator. As shown in Fig. 2a , estimates of ART-coverage among MSM varied across regions, while for virological suppression among those on ART, levels were generally high, and differences between regions smaller. The highest ART-coverage among MSM was observed in East Central Europe, where 87.2% (n ¼ 641) of those in care received ART, and of those, 91.6% (n ¼ 587) had a suppressed viral load. Among MSM, the lowest ART-coverage (73.6%), but the highest levels of virological suppression on ART (95.9%) were found in Western Europe, while the lowest level of virological suppression among MSM was observed in Eastern Europe (87.3%).
Differences across regions were more pronounced for people infected through IDU or heterosexual contact, and variation in the percentages reaching virological suppression was particularly large (Fig. 2b, c 
Within-region variation between transmission categories
Our results showed that overall ART-coverage and virological suppression varied at the regional level. However, we also found regional differences across 
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Virologically suppressed among those in care transmission categories, and formal tests for interaction between transmission category and region indicated that the size of these differences varied significantly by region (global P for interaction P ¼ 0.0148 for ART-coverage, P ¼ 0.0006 for virological suppression). Within-regional variation in the odds of receiving versus not receiving ART and in the odds of being virologically suppressed versus unsuppressed on ART is shown in Figs. 3 (Fig. 3a) . We found no evidence of differences across transmission categories in Western Europe in the odds of being virologically suppressed ( Fig. 4a) . In Northern Europe, where ART-coverage was higher, people infected through heterosexual contact were also more likely to receive ART than MSM [aOR 1.68 (95% CI 1.25-2.26)] (Fig. 3c ). After adjustment, there was some evidence to suggest that people in this region infected through IDU were more likely than MSM to receive ART [aOR 1.40 (95% CI 0.99-1.96)], whereas the odds of having a suppressed viral load on ART were similar across transmission categories in Northern Europe (Fig. 4c) .
In Southern and East Central Europe, adjusted estimates showed no evidence of differences in ART-coverage across transmission categories (Fig. 3b, d ). By contrast, after adjustment, there was evidence to suggest that those infected through heterosexual contact were significantly less likely to achieve virological suppression in both Southern and East Central Europe (Fig. 4b, d ). (Fig. 4e) . Again, CIs for these results were wide, which may partly be due to low numbers in this region.
Sensitivity analyses
We assessed the effect of categorizing missing HIV-RNA as unsuppressed and found that estimates did not change much when limiting analyses to those with available HIV- RNA measurements in the study period (Fig. 4a-e) . Thus, differences in the availability of HIV-RNA measurements did not account for the observed differences between transmission groups.
To account for possible collinearity between HCVcoinfection and the IDU transmission category, we also performed a posthoc sensitivity analysis excluding HCV coinfection from adjusted models. When HCV-coinfection was not adjusted for, we no longer saw any differences between unadjusted and adjusted estimates among IDU, that is, most of the difference between unadjusted and adjusted estimates was due to the inclusion of the HCV-variable. For MSM and heterosexuals, adjusted estimates remained the same as in the primary analysis.
Discussion
We assessed variation in ART-coverage and virological suppression across key populations, as defined by selfreported HIV transmission categories, in a large, multinational cohort study. We found that the percentage receiving ART among those in care, the percentage virologically suppressed on ART and the pattern of differences across transmission categories varied by geographical region. Within EuroSIDA as a whole, the highest heterogeneity for any transmission category was observed among those infected through IDU, whereas regional variation among MSM was less pronounced. However, we also found that members of different key populations may receive different care within the same region. In Western and Northern Europe, people infected through heterosexual contact were more likely than other transmission categories to receive ART, while MSM had the highest ART-coverage in Eastern Europe. Furthermore, we found no differences in the high levels of virological suppression across transmission categories in Western and Northern Europe, whereas the picture was more diverse in other regions.
Our findings highlight some important points: first, our data confirm the heterogeneity of the HIV epidemic and underline the need to target and differentiate health services to fit the local epidemic [1, 7, 13] . Second, supporting the findings of others, it is possible to achieve equity in ART-coverage and virological suppression across transmission categories [14] . Third -and further to our previous studies on regional differences [4] -this study shows that ART-coverage and virological suppression varied across transmission categories within each region. This indicates that variation in the continuum of HIV care may go beyond regional differences in economy and a limited supply of ART [15] . Our findings also highlight that some regions must focus on scaling up ART-programmes, while others may benefit from a particular focus on adherence counselling and support [1].
Achieving high levels of virological suppression among all living with HIV remains crucial; both for individual health benefits and for reducing the risk of onward transmission. Our study illustrates that there are still opportunities to improve the virological response to ART. For example, ART-coverage was high and comparable across all transmission categories in East Central Europe, but levels of virological suppression were lower among people in the IDU and heterosexual categories than among MSM in this region. A similar pattern was observed among heterosexuals in Southern Europe. Importantly, sensitivity analyses showed that neither the observed disparities across transmission groups, nor regional differences in levels of virological suppression were explained by differences in the availability of HIV-RNA measurements. Our findings thus highlight the importance of increasing focus on differentiated treatment counselling and adherence support, targeting those who need it the most.
People infected through IDU were the least likely to receive ART and achieve virological control in our study. However, our estimates were higher than in some other studies [6, 16, 17] , and it is important to keep in mind that there may be differences in testing and linkage to care across clinics and countries in EuroSIDA. A recent study found that IDU tended to be underrepresented in European cohorts when compared against a gold standard of ECDC surveillance data [18] , and several studies have shown that both testing and linkage rates are particularly low among people who inject drugs. Further, people enrolled into EuroSIDA must have had a visit to a collaborating clinic and must agree to participate in the cohort. EuroSIDA participants infected through IDU may therefore represent a selected population of the whole IDU-population in each country, characterized by a higher ability to remain in HIV care, and ultimately by better long-term clinical outcomes. Consequently, our data likely overestimate outcomes for people infected through IDU.
Our sensitivity analysis showed that adjusting for HCVcoinfection attenuated differences in ART-coverage and virological suppression between IDU and MSM. Because international treatment guidelines recommended early ART-initiation for HIV/HCV-coinfected individuals throughout the study period, we find it unlikely that the lower odds of receiving ART among IDU were based on HCV-status [19, 20] . Furthermore, a previous Euro-SIDA study found no evidence that HCV-coinfection negatively affects the ability to suppress HIV-RNA [21] . We believe that IDU is more likely a shared risk factor for HCV-infection and poorer access to care, yielding poorer outcomes for people infected with HIV through IDU. However, due to collinearity of HCV-coinfection and IDU, we are unable to formally determine whether differences between IDU and MSM were driven primarily by transmission category or by differences in HCV-infection.
Even if our results cover large between-country and within-country differences, our regional estimates are helpful to highlight gaps in the quality of HIV care [1, 4, 22] . In this context, the climbing HIV epidemic in Eastern Europe should be mentioned. In line with our findings, surveillance data documented a substantial treatment gap in Eastern Europe [1, 2] , and levels of virological suppression that are comparable to our previous findings [4] . However, our study shows that a population average may mask substantial variation across key populations. People infected through IDU and heterosexual contact accounted for comparatively higher proportions of participants in Eastern Europe, at the same time that these people had the lowest levels of ARTcoverage and virological suppression. Understanding how this incongruence may fuel the epidemic will be important. It is well known that people with an active illicit drug use have particularly poor access to integrated care and harm reduction services in some countries in Eastern Europe [23, 24] , which may contribute to the lower treatment and suppression rates in this group. As for the heterosexual transmission category, people in some countries are predominantly migrants infected in highendemic countries [25] , while this group may include sex partners to people with IDU in other countries. Such regional diversity of the heterosexual category may partly explain why levels of ART-coverage and virological suppression for heterosexuals in Eastern Europe differed from other regions. Finally, we noticed that remarkably few MSM were included in Eastern Europe, which may not only be a reflection of the current epidemic in the region but could also reflect misclassification due to fear of stigmatization or criminalization [17, 26] . Although the risk of such misclassification is inherent to self-reported data, we are not aware of other ways to collect information on transmission category.
Some strengths of our study should be mentioned. Although other studies have explored barriers to care for single key populations, this is one of the few studies comparing differences between transmission categories in core HIV care parameters [6, 7, 11, 27, 28] . Furthermore, our study is among few European studies that hold some data on key populations and is among the first to compare across regions of Europe [11, [29] [30] [31] [32] . Third, our standardized data collection overcomes many of the problems, such as a lack of common definitions, often faced when trying to compare quality of care across countries [11, 33] . EuroSIDA data are collected in a standardized manner at the individual level. This is in contrast to many existing studies (including surveillance data) that are the result of cross-sectional surveys often filled in by public health experts, or where data are merged from different data sources [2, 11] . However, our study also has some limitations. Our cohort represents those diagnosed and linked to care, and it will be important to estimate the size of each key population, in addition to obtaining data on populations such as sex workers, prisoners, transgender people and migrants, in order to tailor testing and treatment strategies. These data are not routinely collected in EuroSIDA. Second, people's behaviours are fluid and the HIV-transmission category does not necessarily reflect current behaviour. For example, we were not able to separate people who ever injected drugs from people with an ongoing use; people who may have very different lifestyles, and consequently very different needs. Third, we did not adjust for differences in the type of ART-regimen, which may also affect the odds of having a suppressed viral load, for example due to well known interactions between some illicit drugs and antiretrovirals [20, 34] .
In our study, we did not take varying local treatment threshold guidelines into account. Although our data are new, progress is fast, and ART-coverage may have increased since our estimates, as countries increasingly adopt and implement new treatment strategies [1, 35] . On the contrary, although differences in guidelines are likely reflected in our study, they are unlikely to explain the variation we saw between transmission groups. These differences may be explained by factors such as laws and policies criminalizing same-sex behaviour or ongoing substance abuse, deferral of ART due to concerns about nonadherence and various other structural and patientrelated factors that we were not able to account for [7, 16, 24, [36] [37] [38] .
From previous studies, we know that clustering of countries into regions may cover potentially large differences between countries in ART-coverage and virological suppression [4] . However, even in a cohort as large as EuroSIDA, it was not possible to present countrylevel data disaggregated by transmission category, which emphasizes the urgent need to increase the availability of data on key populations. It may be debated whether the grouping into five regions used in EuroSIDA is the most appropriate. On the contrary, similarities in both the epidemic, outcomes and health systems structure within regions account for the clustering [12, 39, 40] . Due to an extensive data quality assurance programme, data quality in EuroSIDA is high. Nonetheless, missing data, underreporting or reporting delays may affect the data quality in any cohort and could also affect our results. Finally, clinic characteristics and the number of people included in EuroSIDA vary by country, and EuroSIDA data may not be representative of HIV care within the individual countries. Work is ongoing to understand the representativeness of EuroSIDA data and to explore how cohort data may supplement other data sources to facilitate longitudinal monitoring of HIV-programmes.
Conclusion
We found that levels of ART-coverage and virological suppression varied depending on HIV transmission category, both across and within regions. Overall, people
Variation among HIV key populations Laut et al. 2815 infected through IDU were the least likely to receive ART and to achieve virological suppression on ART, but the pattern varied significantly by region of residence. Our results demonstrate that national estimates of ARTcoverage and virological suppression may represent an average that covers large differences across key populations, highlight that a differentiated HIV-response remains crucial to reaching control of the HIV epidemic and underline that high-quality disaggregated data are needed to inform and strengthen interventions.
